



2022-2023

ANNUAL REPORT

The proud trusted and credible resource
in genomics for over 20 years



TABLE OF CONTENTS

2	DID YOU KNOW?	12	STATEMENT OF FINANCIAL POSITION
3	SUMMARY OF RESULTS	15	BOARD OF DIRECTORS AND COMMITTEES
4	OUR MISSION, OUR VISION AND OUR VALUES COMMITMENT TO EDI	16	OUR TEAM
5	MESSAGE FROM THE CHAIR OF THE BOARD OF DIRECTORS	17	CORPORATE INFORMATION
6	MESSAGE FROM THE PRESIDENT AND CEO		
7	MANAGEMENT COMMITTEE		
8	HIGHLIGHTS		



DID YOU KNOW?

THREE LETTERS THAT CHANGE THE WORLD: DNA

Genomics refers to the study of the complete set of genetic information of all living beings, encoded in their DNA and other similar molecules, such as RNA and proteins. Our current technological capacity to read this “code” of life is unprecedented and continues to develop at a rapid pace. The knowledge gained through genomics holds the key to innovative solutions in a wide range of sectors and offers tremendous opportunities for economic growth and better quality of life for people the world over..

GÉNOME QUÉBEC

Since its inception in 2000, Génome Québec has helped Québec make great strides in genomics research. Over the years, many areas of activities have benefited from research funded by Génome Québec and its Centre d'expertise et de services (CES) located at CHU Sainte-Justine. Genomics is now seen as a promising technology for the economy, more specifically in health, agrifood, forestry and the environment.


Génome Québec plays a leading role in genomics research teams by funding the most relevant research and guiding researchers to achieve world-class expertise.

Québec has every reason to be proud of the success of our genomics researchers, who are recognized internationally for the quality of their work and for the major discoveries made right here at home. Their expertise is one of the reasons Québec is considered a leader in this field.

Over the past 20 years, more than \$1 billion has been invested in genomics through Génome Québec. This includes investments from the provincial and federal governments, as well as other partners.



SUMMARY OF RESULTS



OUR MISSION

Génome Québec's mission is to catalyze the development and excellence of genomics research and promote its integration and democratization. It is a pillar of the Québec bioeconomy and contributes to Québec's influence and its social and sustainable development.

OUR VISION

Genomics-driven innovations will improve health care service delivery, support agrifood, environmental and forest management practices and enhance public policies.

OUR VALUES

Excellence Openness Creativity Integrity Ethics

COMMITMENT TO EDI

For many years now, Canadian and Québec research funding organizations have been mobilizing to create a culture of inclusion and foster the integration of EDI principles in the design of research programs and in funding practices. Their efforts are focused on ensuring equitable access to financial support for all members of the research community, but also on promoting inclusion, diversity and equity in project design.

It's in this context that Génome Québec created an EDI committee with the mandate of exploring various options for embedding the principles of equity, diversity and inclusion into organizational practices. The committee worked with the help of EDI consultants to initiate a rich and productive discussion.

Génome Québec's commitment to EDI: **"Génome Québec is recognized as a socially responsible organization that respects and adopts the values of equity, diversity and inclusion, thereby contributing to a more equitable society. Génome Québec is committed to promoting equity, diversity and inclusion in its ecosystem through concrete actions that highlight the wealth of humanity."**





Anie Perrault

ANIE PERRAULT

"I am lucky to chair a board of directors made up of such highly qualified members, who are committed to Génome Québec's mission and its success. Three of their terms will come to an end in June 2023, so I'd like to take this opportunity to thank them officially for their valuable and relevant contributions. Thank you to Isabelle Bouffard, Sylvain Moineau and Jennifer Stoddart."

MESSAGE FROM THE CHAIR OF THE BOARD

BUILDING ON SOLID FOUNDATIONS – A NEW ERA FOR GÉNOME QUÉBEC!

2022-2023 was a year of transition. With the retirement of the President and CEO, the Board of Directors quickly went into recruitment mode. The board members appointed to lead this process did so rigorously and according to best practices, a comprehensive process that ended with the appointment of Josette-Renée Landry, the first woman to take the helm of Génome Québec. Her appointment was publicly confirmed last November, and she took up her position on January 23, 2023.

However, an interim period was needed to keep us on course between Daniel Coderre's retirement in October and the arrival of the new president and CEO. The challenge was deftly and brilliantly taken up by Marie-Kym Brisson, Vice President of Strategic Development and Public Affairs. This interim period was marked by several important strategic files, including the preparation and filing of the three-year funding application to the Ministère de l'Économie, de l'Innovation et de l'Énergie, many governmental meetings, the hiring of a human resources director, and other issues requiring intervention by the interim president and CEO. I want to thank Marie-Kym, as well as the other vice presidents, Stéphanie Lord-Fontaine, Marc Bergeron and Patrick Blondin, for working closely together to reach all the goals that had been set and hand Josette-Renée the keys to a healthy organization with the wind in its sails.

In addition to the \$50 million in funding received in March 2023 after the three-year funding application was filed, I want to highlight some of the Génome Québec teams' other achievements. I am thinking in particular of the great performance of the Scientific Affairs team, which, through the Genomics Integration Program (human health and non-human health streams), was able to fund for 22 promising new projects for a total investment of \$6.7 million, in collaboration with the Fonds de recherche du Québec - Nature et technologies (FRQNT). The technology centres

team, for its part, served 958 research teams throughout the year and completed its thousandth sequencing run with the Illumina NovaSeq 6000 machine, a first in Canada. Known for its quality educational activities, the Strategic Development and Public Affairs team was asked to conduct scientific workshops as part of the Public Action Zone at the UN Biodiversity Conference (COP15), an excellent opportunity to demonstrate the impact of genomics on the environment. Also worthy of mentioning is a new collaboration with Cree communities to implement a citizen science pilot project called "Mission eDNA." Finally, I want to commend the Finance and Administration team on the sound financial and risk management it provides.

To close, I look to the future with great enthusiasm, with Génome Québec's upcoming 2023-2028 strategic planning exercise, under the leadership of our new president and CEO and with the input of all the board members, who are responsible for adopting the strategic plan. It's a great opportunity to take a step back, consult and propose a distinctive, ambitious vision to make Québec a leader in genomics.



JOSETTE-RENÉE LANDRY

“Génome Québec is in an enviable position of being able to contribute at each stage of the research and innovation chain and in a wide range of sectors. After a few months on the job, I look forward to seeing everything Génome Québec will be able to accomplish in the near future.”

MESSAGE FROM THE PRESIDENT AND CEO

GÉNOME QUÉBEC: AN ENVIABLE REPUTATION AND A BRIGHT FUTURE

My arrival at the head of Génome Québec was a sign of big changes for 2023. I am excited to join such a highly qualified team of motivated and dedicated executives, directors and employees. I want to thank them for their warm welcome and for the time they have given me to discuss various files.

Génome Québec's reputation for excellence is indisputable. The unique potential of being able to fund the advancement of knowledge while also contributing to it technologically thanks to Génome Québec's Centre d'expertise et de services had a big impact on my interest in joining the organization. Génome Québec is in an enviable position of being able to contribute at each stage of the research and innovation chain and in a wide range of sectors. Indeed, I was pleased to look over, on my arrival, the Ministère de l'Économie, de l'Innovation et de l'Énergie's (MEIE) latest evaluation of the organization.

Over the last five years, Génome Québec was able to surpass the targets set by the MEIE. Whether in terms of its relevance to its ecosystem, links with government strategies, creation of socioeconomic value, efficiency in the management of its programs and competitions, or contribution to the advancement of scientific knowledge, Génome Québec achieved the performance indicators set by the MEIE with flying colours. These excellent results gained us, among other things, an initial funding contribution of \$50 million to begin our new three-year financial assistance agreement. This funding will allow us to maintain our workforce but also to begin working on new initiatives that will complement the organization's existing projects and investments.

After reviewing the results of the MEIE evaluation, I humbly admit that Génome Québec's ability to support so many links in the scientific research chain, both in human health and in agriculture, forestry and environment, was something of a revelation for me. Having been a part of Génome Québec's ecosystem in the past, I knew about the

funding programs and the quality of the support the team offers, but I didn't expect to see such a potential for growth. That's why I am very enthusiastic about the next few years. The strategic planning review set for 2023 will certainly enable us to lay the groundwork for a solid and inspiring roadmap for the organization and its ecosystem. This exercise will help us better understand the community's needs and guide the organization's efforts in the coming years. For example, we want to continue to support the development of genomic medicine, but also help boost socioeconomic value in sectors where genomics offers an underexplored potential for innovation, like agriculture, forestry and biodiversity conservation.

After a few months on the job, I look forward to seeing everything Génome Québec will be able to accomplish in the near future. It's time to take advantage of more than 20 years of genomics investments in Québec to drive scientific innovation and continue to find solutions to the challenges our society is facing.

I'll conclude by thanking the members of the Board of Directors for their support and their confidence, the Management Committee, and the entire Génome Québec team, for helping maintain such a high standard of excellence in all our organization's spheres of activity.



MANAGEMENT COMMITTEE

(from left to right on the photo)

Patrick Blondin

Marc Bergeron

Marie-Kym Brisson

Stéphanie Lord-Fontaine

Josette-Renée Landry

A SOLID TEAM WITH A WEALTH OF EXPERIENCE

Génome Québec was born from the initiative of visionaries and builders among elected officials, academics, researchers and business people with a dream of fostering genomics research in Québec, a still underdeveloped sector in the 1990s.

Today, it's clear that we have made great breakthroughs in this field through our research ecosystem. You could say that genomics is in our organization's DNA!

Génome Québec is tasked with the challenge of showcasing genomics to turn it into a driver for economic development. In addition to funding research activities in genomics, our priority is to foster the emergence of its applications and increase its environmental and social benefits in our communities. It is only by working together to mobilize our networks and resources that we can leverage genomics to help improve the lives of Québécois in a wide range of application areas.

Made up to five people with distinctive backgrounds, Génome Québec's Management Committee embodies the importance of complementarity between team members to carry out the organization's mission.

JOSETTE-RENÉE LANDRY

President and CEO

Previously Chief Executive Officer of the Institut du Savoir Montfort and Vice President of Research and Education at Hôpital Montfort, Josette-Renée is also the founder of Streamline Genomics, a digital health company combining precision medicine with artificial intelligence. She has many other feathers in her cap, including having served as associate professor at the Université de Montréal's Faculty of Medicine and adjunct professor at the University of Ottawa's Faculty of Health Sciences.

MARC BERGERON

Vice President, Finance and Administration

Marc has 20 years of experience in the strategic management of financial services and 10 years as a comptroller and in other accounting roles within major international organizations. Before joining the Génome Québec team in 2017, he served as Manager, Corporate Strategic Initiatives, at Roche Diagnostics.

PATRICK BLONDIN

Vice President, Technology Centres

Patrick worked in the private sector with Boviteq for 18 years, mainly in research and development and as interim director of operations. He was promoted to the post of Vice President, Research and Innovation, in 2018. He has also authored more than 80 research articles.

MARIE-KYM BRISSON

Vice President, Strategic Development and Public Affairs

Marie-Kym Brisson has more than 25 years of experience in public affairs and communications in areas shaped by various social and political agendas in Québec, Canadian and international contexts. For the past 15 years, she has worked in the research and innovation sector, where she has dedicated herself to the strategic development of genomics in Québec.

STÉPHANIE LORD-FONTAINE

Vice President, Scientific Affairs

Stéphanie is a seasoned research administrator with more than 20 years of experience in academic and biopharmaceutical circles and in research funding organizations. She worked with Génome Québec from 2007 to 2017 as senior director in the Scientific Affairs team. In her time as director general at Oncopole, she participated in the design and launch of many large-scale projects in oncology in Québec.



HIGHLIGHTS



The overall success rate for Québec researchers hit 45% in Génome Québec's Genomic Application Partnership Program (GAPP)


– This year, seven projects were financed for a total budget of \$36M in Québec out of a total Canadian budget of \$80.3M

- Followed by a portfolio of 133 projects and platforms, of which 28 were launched during the year
- Launch of Genome Canada's first challenge with its new research funding model: interdisciplinary challenge teams for the Climate-Smart Agriculture and Food Systems initiative
- Two Québec research teams were selected to receive funding as part of this competition, representing a total budget of \$13M in Québec

- Funding for 22 new projects under the Genomics Integration Program (human health and non-human health streams), for a total investment of \$6.7M in collaboration with the Fonds de recherche du Québec - Nature et technologie (FRQNT)
- New competition to develop artificial intelligence tools applied to omics data - Total funding of nearly \$2.9M in collaboration with IVADO
- Launch of the Génome Québec competition: Genomic solutions for the identification, characterization and surveillance of antimicrobial resistance and emerging pathogens

- Creation of Genovalia, the very first centre dedicated to the production, processing and exploitation of non-human genomic data in Québec, in collaboration with Université Laval
- Zone Agtech and Génome Québec announce a partnership with the goal of accelerating the development of Québec genomic solutions applied to the agrifood sector

INCREASE IN THE NUMBER OF ACTIVE PROJECTS IN THE PORTFOLIO



HIGHLIGHTS




8.7% growth in our workforce: 74 staff members at the end of the last fiscal year

- Return to the office in hybrid mode in June 2022 for the Administrative Centre staff, who had been teleworking since the beginning of the pandemic
- Improved benefits offering to encourage support, flexibility and work-life balance
- Predominance of women in management positions



Arrival of Josette-Renée Landry, new president and CEO

- Retirement of Daniel Coderre
- Renewal of the financial agreement with the Ministère de l'Économie, l'Innovation et de l'Énergie
- Adoption of an action plan on equity, diversity and inclusion



\$69M in investments


- General and administrative costs of 4.39%
- Continued growth in its activities



Mission eDNA: 48 participating classes in 20 schools

- Scientific workshops at the COP15 Public Action Zone: a total of 2,154 people visited the event
- Rollout of the Mission eDNA activity in First Nations communities, with seven participating classes in two Cree communities

- Participation in the sixth edition of the Montréal Science Centre's Women and Girls of Science event
- Creation and launch of the first three episodes of the podcast series "ADN : 3 lettres qui changent le monde"




HIGHLIGHTS



\$14.8M in revenues

- Construction of new office spaces for the Centre d'expertise et de services (CES)
- 958 research teams served by the CES and the biobank, of which 53% are from Québec
- 1,493 samples sequenced under the GenoRef-Q initiative
- Thousandth sequencing run completed with the Illumina NovaSeq 6000 machine, a first in Canada
- Passed the milestone of 650 sequencing runs with the PacBio Sequel II
- First in Québec to acquire the Illumina NovaSeq X Plus
- Addition of an extraction service at the Génome Québec and CIUSSS du Saguenay-Lac-Saint-Jean Biobank

ORIGIN OF THE 958 ANNUAL USERS




HIGHLIGHTS



\$50M received from the Ministère de l'Économie, de l'Innovation et de l'Énergie after the filing of the three-year funding application

- Creation and launch of an internal portal for staff members
- Complete overhaul of the website
- 20% average growth in subscribers on social media
- Collaboration with the Ministère des Relations internationales et de la Francophonie to create information packages for Québec delegations abroad about the potential of genomics
- Collaboration with the Ministère de la Santé et des Services sociaux to map out the leading research institutions and genomics companies in Québec
- Creation of two new positions in the team: senior advisor in public affairs, and coordinator in education and communications

SOCIAL MEDIA - SUBSCRIBER GROWTH



FINANCIAL ACTIVITY REPORT

STATEMENT OF FINANCIAL POSITION AS AT MARCH 31, 2023, COMPARED TO 2022 DATA

The statement of financial position as at March 31, 2023 and 2022, and the income statement below for the fiscal years ending on March 31, 2023 and 2022, are provided for information purposes only and do not replace G enome Qu ebec's complete audited statements.

G enome Qu ebec's complete financial statements were audited by KPMG LLP, chartered professional accountants, and were the subject of a report on June 16, 2023.

ASSETS

	2023	2022
Current assets		
Cash and cash equivalents	\$58,298,377	\$2,578,648
Short-term investments	\$24,317,497	\$54,004,817
Accounts receivable	\$3,235,894	\$2,606,351
Work in progress	\$536,941	\$345,821
Contributions to be received	\$329,000	\$25,000
Advances to genomics research projects	\$6,571,375	\$7,997,513
Stocks	\$1,072,458	\$1,547,288
Prepaid expenses	\$250,751	\$730,108
	\$94,612,293	\$69,835,546
Long-term investments	-	\$2,047,588
Capital assets	\$7,413,158	\$6,497,406
	\$102,025,451	\$78,380,540



FINANCIAL ACTIVITY REPORT

LIABILITIES AND NET ASSETS

	2023	2022
Current liabilities		
Accounts payable and accrued liabilities	\$5,652,263	\$4,199,074
Obligations from an agreement	-	\$394,167
Deferred revenues	\$443,764	\$502,512
	\$6,096,027	\$5,095,753
Deferred contributions - Future expenses	\$82,593,774	\$60,276,625
Deferred contributions - Capital assets	\$4,123,094	\$4,234,713
Deferred lease inducements - leasehold improvements	\$294,595	\$341,535
Deferred lease inducements - other	\$515,407	\$320,934
Obligation arising from a long-term agreement	-	\$585,336
	\$93,622,897	\$70,854,896
Net assets		
Unrestricted	\$3,267,637	\$1,828,149
Restricted - Invested in capital assets	\$2,995,469	\$941,655
Restricted - Technology investment and contingency funds	\$1,982,523	\$3,422,689
Restricted - Research projects and other initiatives	\$156,925	\$1,333,751
	\$8,402,554	\$7,525,644
	\$102,025,451	\$78,380,540



FINANCIAL ACTIVITY REPORT

INCOME STATEMENT

	2023	2022
Revenues		
Amortization of deferred contributions related to future expenses	\$29,898,958	\$30,327,800
Amortization of deferred contributions related to capital assets	\$1,333,916	\$1,298,804
Investment and intellectual property revenues	\$1,547,585	\$1,930
Revenues from technology centres	\$14,805,597	\$17,273,696
	\$47,586,056	\$48,902,230
Expenses		
Genomics research projects	\$23,033,398	\$22,842,690
Research projects - Québec innovant et en santé	\$41,360	-
Technology centres operational costs	\$17,645,727	\$20,388,482
General and administrative expenses	\$3,028,483	\$2,695,928
Strategic development	\$628,019	\$509,658
Loss on disposal of capital assets	\$364,191	-
Depreciation of capital assets	\$1,333,916	\$1,285,960
Depreciation of restricted capital assets	\$634,052	\$358,659
	\$46,709,146	\$48,081,377
EXCESS OF REVENUES OVER EXPENSES	\$876,910	\$820,853



BOARD OF DIRECTORS AND COMMITTEES

BOARD OF DIRECTORS

Anie Perrault, LL.L., ASC
Chair of the Board
Strategic Consultant, Public Affairs
Accredited mediator, Canadian Human Rights Tribunal

Alain Bourque
Vice Chair of the Board
Executive Director, Ouranos

Jean Brunet
Secretary of the Board
Managing partner, Stein Monast LLP

MEMBERS OF THE BOARD

Isabelle Bouffard, B.Sc.
Director, Direction recherches et politiques agricoles, Union des producteurs agricoles

Lynda Durand, LL. B., ASC

Jean-François Éthier, MD, CM, PhD, FRCPC
Clinical Researcher and Associate Professor, Department of medicine, Université de Sherbrooke

Michel Fortin, CPA, CA, ICD.D, BCA
President and Chief Executive Officer, EVAH Corp.

Geneviève Guertin
Vice-President, Investments - Life Sciences, Fonds de solidarité FTQ

David Jarry, M.Sc., LL.M.
BDO, Montréal

Jennifer Stoddart, OC, Ad.E.
Invited Scholar, Centre of Genomics and Policy, McGill University

Marie-Paule Jeansonne, LL.B., MIA
VP Strategy, Impact and Sustainability, Mila

Josette Renée-Landry, PhD, MBA
President and CEO, Génome Québec

Sylvain Moineau, OC, PhD, FRSC
Full Professor, Département de biochimie, de microbiologie et de bioinformatique, Université Laval

Caroline Quach, MD, M.Sc., FRCPC, FSHEA, MACSS, FAMMI
Full Professor, Département de microbiologie, infectiologie et immunologie, Département de pédiatrie, Université de Montréal

Rémi Quirion, PhD, CQ, OC, FRSC
Chief Scientist, Fonds de recherche du Québec

Marco Blouin, PhD
General director, Ministère de l'Économie, de l'Innovation et de l'Énergie, Science and Innovation Branch

Rob Annan, PhD
President and CEO, Genome Canada

Hélène Desmarais, CM, LL.D.
CEO and Chair of the Board of Administration, Centre d'entreprises et d'innovation de Montréal

FINANCE COMMITTEE

Isabelle Bouffard, B.Sc.
Chair of the Committee

Geneviève Guertin

Alain Bourque, M.Sc.
Chair of the Committee

Jean Brunet
Secretary to the Committee

Lynda Durand, LL.B., ASC

Josette Renée-Landry, PhD, MBA

Anie Perrault, LL.L., ASC
Chair of the Board

Jean Brunet
Secretary to the Committee

Josette Renée-Landry
President and CEO

Marc Bergeron
Vice President, Finance and Administration

Patrick Blondin
Vice President, Technology Centres

Alison Symington, PhD
Chair of the Committee
Strategic Life Science Consultant

Robert Cook-Deegan, MD
School for the Future of Innovation in Society and Consortium for Science, Policy & Outcomes Arizona State University, United States

Evan Fraser, PhD
Arrell Food Institute, University of Guelph, Canada

David Jarry, M.Sc., LL.M.

Marie-Paule Jeansonne, LL.B., MIA

Sylvain Moineau, OC, PhD, FRSC

Anie Perrault, LL.L., ASC

Caroline Quach, MD, M.Sc., FRCPC, FSHEA, MACSS, FAMMI

Jennifer Stoddart, OC, Ad.E.

Isabelle Bouffard, B.Sc.

Alain Bourque, M.Sc.

Josette Renée-Landry, PhD, MBA

Marie-Kym Brisson
Vice President, Strategic Development and Public Affairs

Stéphanie Lord-Fontaine
Vice President, Scientific Affairs

Susan K. Gregurick, Ph. D.
Office of Data Science Strategy
National Institutes of Health Research, United States

Susannah Tringe, PhD
DOE Joint Genome Institute
Lawrence Berkeley National Laboratory, United States

Owen White, PhD
Director of Bioinformatics, School of Medicine, University of Maryland, United States

GOVERNANCE, NOMINATION AND HUMAN RESOURCES COMMITTEE

EXECUTIVE COMMITTEE

MANAGEMENT COMMITTEE

STRATEGIC AND SCIENTIFIC ADVISORY BOARD (SSAB)

BOARD MEMBER EMERITUS



OUR TEAM

ADMINISTRATIVE CENTRE

Beauchemin, Mathieu
Bergeron, Marc
Bergeron, Valérie
Bilodeau, Danielle
Bouchard, Diane
Brisson, Marie-Kym
Cheuk, Arnaud
Choquette, Marie-Paule

Ciurli, Cristina
Dumoulin-Gagnon, Justine
Fournier, Hélène
Gascon, Antoine
Iglesias, Diana
Josepovic, Charlotte
Kozubska, Dominika
Landry, Josette-Renée

Lescarbeau, France
Lessard, Darie
Lord-Fontaine, Stéphanie
Mvié-Lépine, Cynthia
Petit, Guillaume
Poirier Stewart, Noémie
Roy, Alexandra
Sabatier, Laetitia

Sabeh, Michaël
Saleh, Fady-Abanob
Spilker, Annina
Telekawa, Caroline
Trudel, Vincent
Van, Tu Linh
Vo, Thi Yen Nhi

CENTRE D'EXPERTISE ET DE SERVICES GÉNOME QUÉBEC

Bacot, François-Marie
Blais, Véronique
Blondin, Patrick
Boisvert, Jacques
Bouchard, Alex
Brunet, Sébastien
Catudal, Valérie
Croitoru, Antonina
Daoust, Philippe

DonPierre, Geneviève
Fontaine, Joëlle
Fréchette, Rosalie
Geneau, Geneviève
Guillet, Isabelle
Hachmieh, Lynn
Hamel, Nathalie
Joseph, Kanesica Benia
LaBoissière, Sylvie

Landry, Julie
Larbi, Tinhinane
Lavoie, Martine
Lobo De Souza, Kelly Rose
Malette, Claire
Manna, Erika
Massé, François
Michaud, Marc
Montpetit, Alexandre

Poirier, Jean-Michel
Randrianjanahary,
Zofenozarahasina
Robidoux, Frédéric
Rochon, Katherine
Roland, Sharen Sophie
Ruiz Quispe, Maryorit Yuli
St-Onge, Judith
Suarez, Maria-Laura

Tanguay, Alexandra
Théroux, Jean-François
Trahan, Olivier
Vernet, Berchnaude
Verville, Annie
Zotti, Corine

GÉNOME QUÉBEC AND CIUSSS DU SAGUENAY- LACSAINTE-JEAN BIOBANK

Arsenault, Steve
Mior, Nadia
Simard, Caroline
Tremblay, Nancy



CORPORATE INFORMATION

For more information, please contact:

Antoine Gascon

Specialist, Communications and Public Affairs

T 514-377-5613

agascon@genomeQuebec.com

THANKS TO OUR PARTNERS

Québec 



GÉNOME QUÉBEC HEAD OFFICE

630 René-Lévesque Blvd West, Suite 2660

Montréal, Québec H3B 1S6

T 514-398-0668

gqinfo@genomeQuebec.com

genomeQuebec.com

CENTRE D'EXPERTISE ET DE SERVICES GÉNOME QUÉBEC

3175 Chemin de la Côte-Sainte-Catherine

Montréal, Québec H3T 1C5

T 514-398-7211

infoservices@genomeQuebec.com

cesgq.com

GÉNOME QUÉBEC AND CIUSSS DU SAGUENAY-LAC-SAINT-JEAN BIOBANK

305 Saint-Vallier Street

Chicoutimi, Québec G7H 5H6

T 514-398-7211

infoservices@genomeQuebec.com

AUDITORS KPMG LLP

600 de Maisonneuve Blvd West, Suite 1500

Montréal, Québec H3A 0A3

kpmg.ca

LEGAL COUNSEL

Jean Brunet

Stein Monast SENCRL

70 Dalhousie Street, Suite 300

Québec, Québec, G1K 4B2

steinmonast.ca

MINISTÈRE DE L'ÉCONOMIE, DE L'INNOVATION ET DE L'ÉNERGIE

710 Place D'Youville, 3rd floor

Québec, Québec G1R 4Y4

economie.gouv.qc.ca

GENOME CANADA

150 Metcalfe Street, Suite 2100

Ottawa, Ontario K2P 1P1

genomecanada.ca





Genome Québec

Serving the community and
future generations



GENOMEQUÉBEC.COM